Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cefoperazone→

Cefoperazone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
62893-19-0
Molecular formula
C25H27N9O8S2
Molecular weight
645.7 g/mol
Drug class
Third-generation cephalosporin beta-lactam antibacterialantipseudomonal activity
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall synthesis by blocking peptidoglycan cross-linking, producing bactericidal activity against susceptible organisms.
Indications / reported uses
  • Treatment of serious infections caused by cefoperazone-susceptible bacteria, including selected respiratory, urinary, intra-abdominal, biliary, skin/soft-tissue and bloodstream infections; products combined with sulbactam have distinct combination-specific spectra and labels

Sources: NLM MeSH — Cefoperazone · PubMed — Cefoperazone clinical pharmacology · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Third-generation cephalosporin beta-lactam antibacterial; antipseudomonal activity

Mechanism of action

Binds penicillin-binding proteins and inhibits bacterial cell-wall synthesis by blocking peptidoglycan cross-linking, producing bactericidal activity against susceptible organisms.

General use cases

  • Treatment of serious infections caused by cefoperazone-susceptible bacteria, including selected respiratory, urinary, intra-abdominal, biliary, skin/soft-tissue and bloodstream infections; products combined with sulbactam have distinct combination-specific spectra and labels

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cefoperazone Environmental Risk Assessment (ERA) (the Cefoperazone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.